JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

JPMorgan Chase & Co. lowered its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 8.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 315,983 shares of the company’s stock after selling 29,790 shares during the period. JPMorgan Chase & Co. owned 0.68% of 4D Molecular Therapeutics worth $3,416,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in FDMT. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in 4D Molecular Therapeutics by 10.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock worth $14,819,000 after purchasing an additional 65,000 shares in the last quarter. Barclays PLC grew its position in shares of 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock worth $1,241,000 after buying an additional 67,202 shares during the period. Novo Holdings A S increased its stake in shares of 4D Molecular Therapeutics by 7.1% in the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after acquiring an additional 100,000 shares in the last quarter. nVerses Capital LLC purchased a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $40,000. Finally, Braidwell LP boosted its stake in 4D Molecular Therapeutics by 231.7% during the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after acquiring an additional 855,990 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on FDMT shares. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $40.00 to $15.00 in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada lowered their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, Chardan Capital restated a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Stock Down 2.1 %

Shares of FDMT opened at $4.58 on Friday. 4D Molecular Therapeutics, Inc. has a 52 week low of $4.50 and a 52 week high of $36.25. The stock has a market cap of $211.73 million, a price-to-earnings ratio of -1.61 and a beta of 2.81. The business has a 50-day simple moving average of $6.66 and a two-hundred day simple moving average of $11.55.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.